Stockscreener 앱 받기
0.39
1.30%
0.005
시간 외 거래:
.38
-0.01
-2.56%
전일 마감가:
$0.385
열려 있는:
$0.3834
하루 거래량:
2.48M
Relative Volume:
0.81
시가총액:
$48.61M
수익:
$36.86M
순이익/손실:
$-171.67M
주가수익비율:
-0.26
EPS:
-1.5
순현금흐름:
$-171.05M
1주 성능:
+8.88%
1개월 성능:
+9.95%
6개월 성능:
-82.43%
1년 성능:
-85.92%
1일 변동 폭
$0.3573
$0.39
1주일 범위
$0.303
$0.424
52주 변동 폭
$0.2589
$2.83
Mersana Therapeutics Inc Stock (MRSN) Company Profile
명칭
Mersana Therapeutics Inc
전화
617-498-0020
주소
840 MEMORIAL DRIVE, CAMBRIDGE
MRSN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
0.39 | 44.94M | 36.86M | -171.67M | -171.05M | -1.50 |
|
ONC
Beigene Ltd Adr
|
236.86 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.18 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2996 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
614.79 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.73 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-06 | 개시 | William Blair | Outperform |
| 2024-11-15 | 재개 | Citigroup | Buy |
| 2024-03-19 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-02-29 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-02-29 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-02-29 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-12-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-07-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-07-27 | 다운그레이드 | Truist | Buy → Hold |
| 2023-07-27 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-06-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-06-15 | 개시 | Guggenheim | Buy |
| 2023-03-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-20 | 개시 | Citigroup | Buy |
| 2022-11-21 | 개시 | Truist | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-08-30 | 개시 | H.C. Wainwright | Buy |
| 2021-03-31 | 개시 | Credit Suisse | Neutral |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-04-29 | 개시 | BTIG Research | Buy |
| 2020-01-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-11-14 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
Mersana Therapeutics Inc 주식(MRSN)의 최신 뉴스
Mersana Therapeutics to Present at Upcoming Investor Conferences | MRSN Stock News - GuruFocus
Mersana Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
Price T Rowe Associates Inc. MD Decreases Stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
William Blair Analysts Lift Earnings Estimates for MRSN - Defense World
Q2 EPS Estimate for Mersana Therapeutics Lifted by Analyst - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $3.67 Average Price Target from Analysts - Defense World
Truist Financial Raises Mersana Therapeutics (NASDAQ:MRSN) Price Target to $10.00 - Defense World
Mersana extends cash runway into mid-2026 as restructuring narrows focus to breast cancer - MSN
Mersana Therapeutics (NASDAQ:MRSN) Earns Outperform Rating from Wedbush - Defense World
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates - MSN
MRSN: Truist Securities Raises Price Target for Mersana Therapeutics | MRSN Stock News - GuruFocus
MRSN: Guggenheim Reiterates Buy Rating with $5 Price Target | MRSN Stock News - GuruFocus
Mersana Therapeutics (MRSN) Target Price Increased by Truist | MRSN Stock News - GuruFocus
Mersana Therapeutics price target raised to $10 from $9 at Truist - TipRanks
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2025 Earnings Call Transcript - Insider Monkey
Truist Raises Price Target on Mersana Therapeutics to $10 From $9, Keeps Buy Rating - marketscreener.com
Truist raises Mersana stock target to $10, maintains Buy rating By Investing.com - Investing.com Nigeria
Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ... - Yahoo Finance
Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace
Earnings call transcript: Mersana Therapeutics reports Q1 2025 loss, stock up 6.14% - Investing.com Nigeria
Truist raises Mersana stock target to $10, maintains Buy rating - Investing.com
Mersana Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
CORRECTIONMersana Therapeutics Provides Business Update and A - GuruFocus
Mersana Therapeutics, Inc. SEC 10-Q Report - TradingView
Mersana Cancer Drug Shows Strong 31% Response Rate in Latest Trial Data, Reports Q1 Financial Results - Stock Titan
Mersana Therapeutics (MRSN) Reports Lower Q1 Revenue and Shares - GuruFocus
Mersana Therapeutics Provides Business Update and Announces Firs - GuruFocus
Mersana Therapeutics Q1 2025 Financial Results and Business Update - TradingView
Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results - GlobeNewswire
Clinical Trial Results: Mersana's New Cancer Drug Achieves 31% Response Rate in Hard-to-Treat Tumors - Stock Titan
Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Report Preview: What to Look For - GuruFocus
Barclays PLC Sells 311,805 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Wedbush Expects Stronger Earnings for Mersana Therapeutics - Defense World
Petri Dish: Cancer biotech cuts staff; Lantheus sells business unit - The Business Journals
Bluebird pleads for deal support; Unity, Mersana lay off staff - BioPharma Dive
Wedbush Cuts Price Target on Mersana Therapeutics to $3 From $4, Maintains Outperform Rating - marketscreener.com
Mersana Therapeutics announces restructuring plans; shares fall - TradingView
Mersana Therapeutics Announces Restructuring and Reprioritization Plan - citybiz
Mersana Therapeutics (MRSN) Announces Major Restructuring Strate - GuruFocus
Mersana Therapeutics Announces Strategic Restructuring and Repri - GuruFocus
Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer | MRSN Stock News - GuruFocus
Mersana Therapeutics announces strategic cutbacks amid economic pressures - Investing.com
Mersana Therapeutics Announces Strategic Restructuring to Extend Cash Runway and Focus on Emi-Le Development - Nasdaq
Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer - GlobeNewswire
Mersana Slashes Workforce by 55%, Doubles Down on Promising Breast Cancer Drug Pipeline - Stock Titan
MRSN stock touches 52-week low at $0.56 amid market challenges - MSN
Mersana Therapeutics Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Mersana Therapeutics Inc [MRSN] stock for 2,061 USD was sold by Mandelia Ashish - knoxdaily.com
Renaissance Technologies LLC Has $867,000 Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics Inc (MRSN) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Mersana Therapeutics (MRSN) Expected to Announce Earnings on Thursday - Defense World
Mersana Therapeutics Inc (MRSN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.33%
1.09%
자본화:
|
볼륨(24시간):